PLBIO(SZ:000403)2023-04-28 16:00Financial Performance - The company's operating revenue for 2022 was ¥2,405,188,425.37, an increase of 21.98% compared to ¥1,971,734,315.85 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥587,131,491.86, representing a growth of 50.14% from ¥391,063,978.44 in 2021[12]. - The net cash flow from operating activities reached ¥524,218,863.43, up 28.42% from ¥408,218,063.31 in the previous year[12]. - The basic earnings per share for 2022 was ¥0.8035, a 44.96% increase from ¥0.5543 in 2021[12]. - The total assets at the end of 2022 amounted to ¥7,982,324,465.77, reflecting a 12.62% increase from ¥7,087,797,976.53 at the end of 2021[12]. - The company reported a weighted average return on equity of 8.90% for 2022, compared to 7.03% in 2021[12]. - In 2022, the company achieved a revenue of CNY 2,405.19 million, representing a year-on-year growth of 21.98%[32]. - The net profit attributable to shareholders reached CNY 587.13 million, with a significant increase of 50.14% year-on-year[32]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 517.57 million, showing a remarkable growth of 99.39%[32]. - Domestic market sales revenue was CNY 2,292.12 million, reflecting a year-on-year increase of 17.31%[32]. - Overseas sales revenue surged to CNY 113.06 million, marking an impressive growth of 534.38% year-on-year[32]. Market and Industry Insights - The blood products market is projected to exceed $47.7 billion globally by 2027, indicating significant growth potential for the company[18]. - The Chinese blood products market is currently valued at over ¥400 billion, with substantial growth opportunities compared to mature markets in Europe and the US[18]. - The company plans to leverage the tightening international supply of blood products to enhance domestic production and export opportunities[18]. - The blood products industry in China has a high entry barrier, with only 28 qualified production enterprises as of now[20]. - The market for blood products in China is expected to grow significantly, with potential market capacity surpassing 100 billion yuan in the future[26]. - The blood products market in China is characterized by long-term supply shortages, with strict regulations on plasma collection and imports[23]. - The industry is witnessing increasing concentration, with major players capturing over 80% of the market share globally[26]. Strategic Initiatives and Partnerships - The company plans to expand its market presence and enhance its product offerings through new technology development and strategic partnerships[3]. - The company has established a strategic cooperation agreement with Xinjiang Deyuan to supply no less than 180 tons of plasma annually for five years[27]. - The strategic partnership with Xinjiang Deyuan has strengthened plasma collection capabilities and improved supply stability[32]. - The company plans to expand its product offerings and enhance brand effects through multi-brand operations and resource integration[36]. - The company is actively pursuing overseas market registration and export opportunities in Southeast Asia, South America, and the Middle East[32]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[97]. Research and Development - The company has a total of 71 authorized patents and is actively developing over 10 products, indicating strong R&D capabilities[35]. - The company is currently in the clinical trial phase for several new blood product lines, aiming to enhance its product offerings and profitability[50]. - The company plans to submit applications for drug registration for several new products, which are expected to enhance its core competitiveness and profit margins[51]. - The company has over 10 products in the rapid development stage, including human prothrombin complex, which is expected to obtain production licensing soon[76]. - Research and development expenses increased by 30%, totaling 150 million RMB, to support new technology initiatives[158]. Governance and Management - The company has established a strong governance structure with experienced board members overseeing its operations[96]. - The company maintained independence from its controlling shareholders in personnel, assets, finance, institutions, and business operations[89]. - The company has a complete and clear ownership of its operational assets, including production equipment and intangible assets[89]. - The company has a robust human resources management system, including independent salary management and accounts[89]. - The company has a management method for subsidiaries to ensure standardized and efficient operations[138]. - The company has a management team with extensive experience in finance and pharmaceuticals, including positions at major financial institutions and pharmaceutical companies[96][97][98]. Financial Management and Audit - The company engaged KPMG Huazhen LLP as its accounting firm for the reporting period[10]. - The audit fee for KPMG Huazhen LLP was CNY 2.2 million for the reporting period[165]. - The total audit fee for the 2022 financial report and internal control audit was RMB 2.2 million, with RMB 1.65 million for the financial report audit and RMB 0.55 million for the internal control audit[169]. - The company maintains an independent financial accounting department and decision-making process[160]. - The company has committed to avoiding or minimizing related party transactions to protect shareholder interests[160]. Shareholder and Dividend Information - The company reported a cash dividend of 0.80 RMB per 10 shares, based on a total of 732,642,692 shares, with no stock bonus issued[2]. - The company’s unallocated profit for the 2022 fiscal year is 1,286,639,844.36 yuan, with 217,808,572.53 yuan available for distribution to shareholders[126]. - The company’s cash dividend distribution accounted for 100% of the total profit distribution amount[126]. - The company has not proposed any cash dividend distribution plan for the previous fiscal year despite having positive distributable profits[125]. Compliance and Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[2]. - The company is committed to adhering to legal regulations and enhancing internal controls to mitigate risks and ensure sustainable development[84]. - The blood products industry faces regulatory risks due to stringent government oversight and evolving policies, which may impact competition and operations[80]. - The company acknowledges the inherent risks in product development, particularly in the innovative biopharmaceutical sector, where high investment and long cycles are common[83]. Social Responsibility and Environmental Initiatives - The company actively participates in social welfare initiatives, including donations for poverty alleviation and healthcare support for patients with hemophilia[152]. - The company has committed to achieving a net profit of no less than RMB 75 million, 120 million, 180 million, and 220 million for the years 2020, 2021, 2022, and 2023 respectively[156]. - The company has received recognition as an advanced unit in legal awareness activities, reflecting its commitment to corporate social responsibility[152]. - The company has implemented environmental protection measures, including wastewater treatment and emissions monitoring, ensuring compliance with regulations[145].